Cannabinoid Hyperemesis Syndrome
Basics
Description
- Cannabinoid hyperemesis syndrome (CHS) is defined by cyclic nausea, vomiting, and abdominal pain typically relieved by hot showers or baths in the setting of chronic cannabis use.
- Easily misdiagnosed as cyclic vomiting syndrome. Patients have chronic cannabis use history, and symptoms may not be relieved by conventional antiemetics or analgesics.
- Patients often remain undiagnosed for a substantial time.
Epidemiology
Incidence
- Cannabis use has been increasing with the legalization of medical and recreational use. In 2017, 30.5 million Americans reported current cannabis use (1).
- CHS and other cannabis-related emergency department visits in areas where cannabis has been legalized have increased significantly.
Prevalence
Up to 2.75 million people in the United States may suffer from CHS (2).
Etiology and Pathophysiology
- The pathophysiology remains unknown, but there have been multiple proposed mechanisms.
- Cannabinoids such as cannabidiol (CBD) at high doses may be proemetic, whereas low doses are antiemetic (3).
- Cannabinoid receptors CB1 and CB2 are located in the CNS and GI system. CB1 receptor activity is thought to be responsible for the effects on cognition, memory, nausea, and vomiting.
- CHS may be due to desensitization or downregulation of CB1 receptors (4).
- G-protein coupled tissue receptors called TRPV1 that are located in the area postrema of the medulla, gastric enteric nerves, and vagal nerves. Prolonged exposure to cannabinoids inactivate TRPV1, which may result in nausea, abdominal pain, and altered gastric motility.
- Nociceptive stimulation through heat (hot showers) or topical capsaicin may relieve symptoms through activation of TRPV1 (5).
Genetics
Cannabis use disorder has a potential hereditary component; the genetic contribution may be greater in adolescents than adults.
Risk Factors
Risk factors for cannabis use disorder include age (highest in 18 to 25 years), male sex, lower socioeconomic status, comorbid psychiatric disorders, and other substance use.
General Prevention
Cannabis cessation or avoidance
Commonly Associated Conditions
- Substance use disorders
- Delayed gastric emptying
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Domino, Frank J., et al., editors. "Cannabinoid Hyperemesis Syndrome." 5-Minute Clinical Consult, 33rd ed., Wolters Kluwer, 2025. Medicine Central, im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/1688247/all/Cannabinoid_Hyperemesis_Syndrome.
Cannabinoid Hyperemesis Syndrome. In: Domino FJF, Baldor RAR, Golding JJ, et al, eds. 5-Minute Clinical Consult. Wolters Kluwer; 2025. https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/1688247/all/Cannabinoid_Hyperemesis_Syndrome. Accessed October 7, 2024.
Cannabinoid Hyperemesis Syndrome. (2025). In Domino, F. J., Baldor, R. A., Golding, J., & Stephens, M. B. (Eds.), 5-Minute Clinical Consult (33rd ed.). Wolters Kluwer. https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/1688247/all/Cannabinoid_Hyperemesis_Syndrome
Cannabinoid Hyperemesis Syndrome [Internet]. In: Domino FJF, Baldor RAR, Golding JJ, Stephens MBM, editors. 5-Minute Clinical Consult. Wolters Kluwer; 2025. [cited 2024 October 07]. Available from: https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/1688247/all/Cannabinoid_Hyperemesis_Syndrome.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Cannabinoid Hyperemesis Syndrome
ID - 1688247
ED - Domino,Frank J,
ED - Baldor,Robert A,
ED - Golding,Jeremy,
ED - Stephens,Mark B,
BT - 5-Minute Clinical Consult, Updating
UR - https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/1688247/all/Cannabinoid_Hyperemesis_Syndrome
PB - Wolters Kluwer
ET - 33
DB - Medicine Central
DP - Unbound Medicine
ER -